NCT05904470 Phase 2 Completed
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Study sponsor: Atea Pharmaceuticals, Inc. · AVIR
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2024-12-09 Actual
Enrollment · participants 275 Actual
Source updated 2025-10-21 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2025-10-21 · 1 field changed
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before Measure: Proportion of Subjects Achieving Sustained Virologic Response at 12 Weeks Post-treatment (SVR12)
+ After Measure: Percentage of Subjects Achieving Sustained Virologic Response at 12 Weeks Post-treatment (SVR12)
Check registry source
Posted 2025-10-07 · 1 field changed
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before Measure: Proportion of subjects experiencing treatment-emergent adverse events
Measure: Proportion of subjects achieving sustained virologic response at 12 weeks post-treatment (SVR12)
+ After Measure: Proportion of Subjects Achieving Sustained Virologic Response at 12 Weeks Post -treatment (SVR12)
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial